Homology Medicines, Inc. (FIXX) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts FIXX Hot Sheet
Join SI Premium – FREE
Homology Medicines, Inc. (NASDAQ: FIXX) reported Q2 EPS of ($0.61), $0.11 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $354 thousand versus the consensus estimate of $864.4 thousand.
For earnings history and earnings-related data on Homology Medicines, Inc. (FIXX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- First Northern Community Bancorp (FNRN) Tops Q3 EPS by 38c
- Mohawk Industries (MHK) Tops Q3 EPS by 14c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
